Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

Introduction Cetuximab is registered for use in colorectal cancer (CRC) patients with RAS wild-type tumours only. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS. We hypothesize that the activitated KRAS pathway in KRAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Baas, J. M., Krens, L. L., ten Tije, A. J., Erdkamp, F., van Wezel, T., Morreau, H., Gelderblom, H., Guchelaar, H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Phase II Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648966/
https://www.ncbi.nlm.nih.gov/pubmed/26386973
http://dx.doi.org/10.1007/s10637-015-0285-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4648966/
https://www.ncbi.nlm.nih.gov/pubmed/26386973
http://dx.doi.org/10.1007/s10637-015-0285-8

Ejemplares similares